SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s Pithampur Unit-3 receives EIR from USFDA

02 Apr 2019 Evaluate

Lupin has received Establishment Inspection Report (EIR) from USFDA for its Pithampur (Unit-3) facility in Indore in the state of Madhya Pradesh. The inspection was conducted between October 8, 2018 to October 18, 2018.  Lupin’s Pithampur Unit-3 is involved in the manufacture of Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Topical Formulations for the regulated markets.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2496.10 -6.80 (-0.27%)
10-Jul-2026 14:02 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1929.40
Dr. Reddys Labs. 1244.65
Cipla 1439.80
Zydus Lifesciences 1148.75
Lupin 2496.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: